Mitochondria of trained skeletal muscle are protected from deleterious effects of statins

Muscle and Nerve

Volumn 46, Issue 3, 2012, Pages 367-373

  Bouitbir, Jamal ^a   Daussin, Frédéric ^a   Charles, Anne Laure ^a   Rasseneur, Laurence ^b   Dufour, Stéphane ^b   Richard, Ruddy ^a   Piquard, François ^a   Geny, Bernard ^a   Zoll, Joffrey ^a  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Exercise training; Glycolytic muscle; Mitochondrial respiration; Oxidative stress; Statins

Indexed keywords

ATORVASTATIN; CYCLOOXYGENASE 1; HYDROGEN PEROXIDE; MESSENGER RNA; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IC 50; IN VITRO STUDY; MALE; MITOCHONDRIAL RESPIRATION; MUSCLE CELL; MUSCLE EXERCISE; NONHUMAN; PERMEABILITY; PLANTARIS MUSCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; HEPTANOIC ACIDS; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; OXYGEN CONSUMPTION; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL ENDURANCE; PYRROLES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84865311331     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23309     Document Type: Article

References (33)

1. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540.
2. Pahan K. Lipid-lowering drugs. Cell Mol Life Sci 2006; 63: 1165-1178.
3. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59: 483-499.
4. Bao N, Minatoguchi S, Kobayashi H, Yasuda S, Kawamura I, Iwasa M, et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J 2007; 71: 1622-1628.
5. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-1437.
6. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
7. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006; 63: 2415-2425.
8. Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun 2005; 338: 1426-1434.
9. Kitahara T, Li-Korotky HS, Balaban CD. Regulation of mitochondrial uncoupling proteins in mouse inner ear ganglion cells in response to systemic kanamycin challenge. Neuroscience 2005; 135: 639-653.
10. Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Mitochondrial reactive oxygen species and Ca2+ signaling. Am J Physiol Cell Physiol 2006; 291: C1082-C1088.
11. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
12. Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett 2010; 199: 287-277.
13. Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a "mitohormesis" mechanism involving reactive oxygen species and PGC-1. Eur Heart J 2011 [Epub ahead of print].
14. Booth FW, Thomason DB. Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. Physiol Rev 1991; 71: 541-585.
15. Zoll J, Koulmann N, Bahi L, Ventura-Clapier R, Bigard AX. Quantitative and qualitative adaptation of skeletal muscle mitochondria to increased physical activity. J Cell Physiol 2003; 194: 186-193.
16. Zoll J, Steiner R, Meyer K, Vogt M, Hoppeler H, Fluck M. Gene expression in skeletal muscle of coronary artery disease patients after concentric and eccentric endurance training. Eur J Appl Physiol 2006; 96: 413-422.
17. Powers SK, Quindry JC, Kavazis AN. Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. Free Radic Biol Med 2008; 44: 193-201.
18. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004; 194: 10-23.
19. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005; 33: 246-257.
20. Kuznetsov AV, Veksler V, Gellerich FN, Saks V, Margreiter R, Kunz WS. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat Protoc 2008; 3: 965-976.
21. Zoll J, Sanchez H, N'Guessan B, Ribera F, Lampert E, Bigard X, et al. Physical activity changes the regulation of mitochondrial respiration in human skeletal muscle. J Physiol 2002; 543: 191-200.
22. Anderson EJ, Neufer PD. Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation. Am J Physiol Cell Physiol 2006; 290: 844-851.
23. Picard M, Godin R, Sinnreich M, Baril J, Bourbeau J, Perrault H, et al. The mitochondrial phenotype of peripheral muscle in chronic obstructive pulmonary disease: disuse or dysfunction? Am J Respir Crit Care Med 2008; 178: 1040-1047.
24. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009; 54: 1891-1898.
25. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418.
26. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
27. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis 2010; 211: 9-14.
28. Daussin FN, Ponsot E, Dufour SP, Lonsdorfer-Wolf E, Doutreleau S, Geny B, et al. Improvement of [Formula: see text] by cardiac output and oxygen extraction adaptation during intermittent versus continuous endurance training. Eur J Appl Physiol 2007; 101: 377-383.
29. Daussin FN, Zoll J, Ponsot E, Dufour SP, Doutreleau S, Lonsdorfer E, et al. Training at high exercise intensity promotes qualitative adaptations of mitochondrial function in human skeletal muscle. J Appl Physiol 2008; 104: 1436-1441.
30. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004; 57: 525-528.
31. Daussin FN, Rasseneur L, Bouitbir J, Lang AL, Dufour SP, Geny B, et al. Different timing of changes in mitochondrial functions following endurance training. Med Sci Sports Exerc 2012; 44: 217-224.
32. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002; 192: 131-137.
33. Kavazis AN. Exercise preconditioning of the myocardium. Sports Med 2009; 39: 923-935.